Dr. Hong Discusses IPI-549 in Advanced Solid Tumors

David S. Hong, MD

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

IPI-549 is an oral selective P13K-gamma inhibitor targeting tumor macrophages. Hong presented on the monotherapy dose-escalation clinical and translational data from a first-in-human study of this inhibitor in advanced solid tumors during the meeting.
Printer Printing...